US appeals court affirms invalidity of J&J Concerta patent
This article was originally published in Scrip
Executive Summary
A US federal appeals court has affirmed the invalidity of the main patent covering McNeil Pediatrics' (Johnson & Johnson) attention-deficit hyperactivity disorder treatment Concerta (methylphenidate HCl extended release tablets), but generic challenger Watson Pharmaceuticals still faces hurdles in bringing its product to market.